Everolimus Plus Bevacizumab in Recurrent Ovarian Cancer
Posted: Monday, January 13, 2020
A phase II study published in Gynecologic Oncology revealed that combining everolimus and bevacizumab in women with recurrent ovarian, fallopian tube, and peritoneal cancers does not seem to improve response compared with bevacizumab alone. However, those who did respond had alterations leading to activation of the mTOR pathway or mutations in homologous recombination.
“Further study of selected patients with alterations in the PI3K/mTOR pathway may document benefit,” stated Sarah E. Taylor, MD, of the University of Pittsburgh and Magee-Womens Research Institute, Pittsburgh, and colleagues.
The open-label, single-institution trial enrolled 50 women with recurrent ovarian, fallopian tube, or peritoneal cancer. All patients received everolimus at 10 mg daily orally and bevacizumab at 10 mg/kg intravenously every 14 days on a 28-day cycle, and treatment continued until disease progression or an adverse event required discontinuation of therapy.
The best-reported responses included 1 complete response, 6 partial responses, and 35 cases of stable disease. After 6 months, 13 patients (26%) were still free of disease progression. Patients with both platinum-sensitive and platinum-resistant disease demonstrated responses, as did some with prior bevacizumab exposure; patients with clear cell cancers were reported to have had the longest responses to treatment. A total of 38 patients discontinued the study due to disease progression.
As for safety, grade 4 (n = 2) and grade 3 (n = 31) toxicities were reported in 25 patients. The most commonly reported toxicities included oral mucositis, fatigue, diarrhea, hypertension, pain, nausea, and anorexia.
Disclosure: For full disclosures of the study authors, visit gynecologiconcology-online.net.
